Close Menu

Carl Icahn is taking another swing at Genzyme; he is going after four seats on Genzyme’s nine-member board — for himself and for three associates, reports the New York Times. Icahn has not said what his plans might be for Genzyme, though the Times notes that when Icahn wins seats on boards, chief executive officers tend to leave and Genzyme’s Henri Termeer isn’t expected to go without a fight. “I’m sure Henri will fight,” says former Genzyme director Constantine Anagnostopoulos.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.

Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.

A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.

In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.